Garetatug rezetecan clinical trials
How each study uses garetatug rezetecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the garetatug rezetecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
10 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 3
Shanghai Hengrui Pharmaceutical Co., Ltd. (4) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Peking University Cancer Hospital & Institute (1) · Beijing GoBroad Hospital (1) · China Medical University, China (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Adebrelimab (2) · Trastuzumab rezetecan (2) · Apatinib (1) · Tegafur (1) · Gimeracil (1) · Oxonic Acid (1) · Oxaliplatin (1) · SHR-1701 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test garetatug rezetecan, phase 3 first.
- Sep 2027SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaPhase 3 · Shanghai Hengrui Pharmaceutical Co., Ltd.
- Nov 2027SHR-A1904 in Advanced Colorectal Cancer: an Exploratory StudyPhase 2 · Peking University Cancer Hospital & Institute
Studies
Open first, then newest update. How each study uses garetatug rezetecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- SHR-A1904 in Advanced Colorectal Cancer: an Exploratory StudyNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07700719Written as SHR-A1904
- A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORSRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT05277168Written as SHR-A1904
- SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06649292Written as SHR-A1904
- A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine CarcinomaNot yet recruitingPhase 2Beijing GoBroad HospitalNCT07520357Written as SHR-A1904 Injection
- A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract CancerRecruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07450976Written as SHR-A1904 for Injection
- A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerRecruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07110571Written as SHR-A1904 for Injection
- SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid TumorRecruitingPhase 1Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06350006Written as SHR-A1904; Adebrelimab
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruitingPhase 2China Medical University, ChinaNCT06881017Written as SHR-A1904
- A Study of SHR-A1904 in Patients With Advanced Solid CancerActive, not recruitingPhase 1Shanghai Hengrui Pharmaceutical Co., Ltd.NCT04877717Written as SHR-A1904
- A Trial of SHR-A1904 in Patients With Advanced Pancreatic CancerStatus unknownPhase 1Shanghai Hengrui Pharmaceutical Co., Ltd.NCT04928625Written as SHR-A1904
Given beside what is tested · 1 — garetatug rezetecan is usual care or a partner of the new treatment
Codes
What other systems call garetatug rezetecan · ClinicalTrials.gg INT016551
- UNII (FDA) FD5J5RLD4EGARETATUG REZETECANOne source FDA
- NCI Thesaurus C181025Garetatug RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FD5J5RLD4E | GARETATUG REZETECAN | One source FDA |
| NCI Thesaurus | C181025 | Garetatug Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.